Upside – $GP +113% (extends a speculative surge after sequential revenue improvement; the filing also flagged going-concern and lender-covenant risks) – $AYTU +46% (agrees to a $2.70-per-share all-cash acquisition) – $SPAI +22% (record Q3 revenue jumped 2,539%, AI gross margin reached 79% and the first Army prime contract was awarded) – $GLAS +13% (Q3 revenue …
Read in context ›Aytu BioScience Stock (AYTU)
Track Aytu BioScience stock through TheStreet Pro's latest coverage, including articles, Daily Diary mentions, TheStreet Pro portfolio activity, contributor watchlist signals, and Pro price levels.
AYTU
Aytu BioScience
healthcare
At close
$1.82
â–² +0.04 (+2.25%)
Nov 16, 4:00 PM ET
Pre-market
$2.66
â–² +0.84 (+46.15%)
Nov 17, 8:46 AM ET
Market Cap
$19.35M
P/E Ratio
—
1Y Return
-12.92%
EPS (TTM)
-$1.67
Read the latest TheStreet Pro articles mentioning Aytu BioScience, including market roundups, portfolio updates, trade ideas, and investing analysis.
Articles
0 articlesNo articles mentioning AYTU yet.
Daily Diary Mentions
1 mentionGLAS Up, BABA Down: Upside, Downside Movers in the Morning